- Details
- Description
INDICATIONS AND USAGE
Erlotinib is a kinase inhibitor indicated for:
· The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
· First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Limitations of Use:
· Safety and efficacy of LuciErlo have not been established in patients with NSCLC whose tumors have other EGFR mutations.
· LuciErlo is not recommended for use in combination with platinumbased chemotherapy.
DOSAGE AND ADMINISTRATION
· NSCLC: 150 mg orally, on an empty stomach, once daily.
· Pancreatic cancer: 100 mg orally, on an empty stomach, once daily.
